Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- GLBS +32.6%, FSCT +7.1%, CLDR +6.3%, SAIC +3.5%, DTEA +1.2%, (also to explore strategic alternatives, which may include a sale or other transaction)
M&A news:
- SIGM +24.1% (Sigma Designs to be acquired by SLAB for $7.05 per share in a cash transaction valued at approx $282 mln; also reported earnings)
Other news:
- STDY +24.2% (receives final minutes from the FDA on the work necessary to resubmit its New Drug Application for Trevyent)
- TROV +22.6% (presents data showing sensitivity of Triple Negative Breast Cancer cell lines to PCM-075 and synergy with Zytiga at San Antonio Breast Cancer Symposium)
- DCIX +21.9% (following GLBS earnings)
- ERYP +20.1% (reports top-line results of Phase 2b study of Eryaspase; did not meet did not meet its primary endpoint of overall survival )
- GLBR +11.1% (after closing near highs - up 200% on the day)
- ALXN +8.1% (Elliott wants changes at ALXN, according to NY Times)
- OLED +6.1% (Universal Display announces the signing of long-term OLED Agreements with BOE Technology Group)
- MNOV +6% (MediciNova reports positive top-line results from clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis; achieved the primary endpoint)
- VSTM +4.5% (Director disclosed purchase of 60538 shares)
- DEA +4% (to join S&P SmallCap 600)
- DRYS +3.8% (following GLBS earnings)
- HIMX +2.8% (responds to Citron allegations; strongly denies allegations of fraud)
- RDUS +2.2% (details recent elacestrant data presentations; to discontinue further evaluation for vasomotor symptoms to focus on development as breast cancer treatment), CUTR +2% (to join S&P SmallCap 600)
- UAL +1.8% (reports November traffic; raises Q4 unit revenue guidance to down 0-2% from down 1-3%; announces new $3 bln share repurchase program; Kate Gebo named executive vice president Human Resources and Labor Relations, replacing Mike Bonds, who announced his retirement earlier this year)
- SGMO +0.9% (receives EMA recommendation of orphan medicinal product designation for investigational genome editing treatments for MPS I And MPS II)
- BA +0.7% (following CEO appearance on MadMoney)
Analyst comments:
- CBIO +9.1% (initiated with a Buy at B. Riley FBR, Inc; tgt $19 (closed at 7.15 on Thurs))
- TRVG +8.9% (upgraded to Buy from Hold at Deutsche Bank)
- BSX +2.7% (upgraded to Strong Buy from Buy at Needham)
- FMSA +2.3% (initiated with a Buy at Seaport Global Securities)
- LC +1.7% (upgraded to Neutral from Sell at Compass Point)
- PRGO +1.2% (upgraded to Buy from Hold at Argus)
- CELG +0.9% (upgraded to Overweight at Atlantic Equities)
- TCP +0.8% (upgraded to Buy from Neutral at Citigroup)